Shares in Schwarz Pharma got another boost today as it reported positive Phase III trials of its lacosamide product in diabetic neuropathic pain.
Earlier this week the German drugmaker reported that the drug was effective in a Phase III trial involving epilepsy patients, and the latest neuropathic pain data put Schwarz firmly on track to file for approval of the drug in the USA and Europe.
The drug is expected to be a big seller for Schwarz, with sales potential of 300 million euros in epilepsy, and a further 600 million euros if it also reaches the market for neuropathic pain.
Schwaz said that at the target dose of 400 mg/day, lacosamide showed a clinically relevant reduction in pain, which just reached statistical significance compared to placebo.
"Based on the convincing entirety of results from the clinical development program we plan to discuss with the authorities filing for lacosamide in diabetic neuropathic pain," said Iris Loew-Friedrich, a member of the executive board at Schwarz.